Cost-Effectiveness Analysis of a Three-Drug Regimen Containing Bevacizumab for the Treatment of Recurrent Pediatric Medulloblastoma in China: Based on a COG Randomized Phase II Screening Trial.

MLA

Chen, Zhaoyan, et al. “Cost-Effectiveness Analysis of a Three-Drug Regimen Containing Bevacizumab for the Treatment of Recurrent Pediatric Medulloblastoma in China: Based on a COG Randomized Phase II Screening Trial.” Frontiers in Public Health, vol. 10, June 2022, p. 914536. EBSCOhost, https://doi.org/10.3389/fpubh.2022.914536.

APA

Chen, Z., Tian, F., & Chen, X. (2022). Cost-Effectiveness Analysis of a Three-Drug Regimen Containing Bevacizumab for the Treatment of Recurrent Pediatric Medulloblastoma in China: Based on a COG Randomized Phase II Screening Trial. Frontiers in Public Health, 10, 914536. https://doi.org/10.3389/fpubh.2022.914536

Chicago

Chen, Zhaoyan, Fangyuan Tian, and Xi Chen. 2022. “Cost-Effectiveness Analysis of a Three-Drug Regimen Containing Bevacizumab for the Treatment of Recurrent Pediatric Medulloblastoma in China: Based on a COG Randomized Phase II Screening Trial.” Frontiers in Public Health 10 (June): 914536. doi:10.3389/fpubh.2022.914536.